In a retrospective analysis of AML17 trial data, patients with AML without the NPM1 mutation demonstrated more benefit from allo-HSCT if MRD-positive (HR 0.72) than MRD-negative (HR 1.68) [68]. This evidence concerns the gene NPM1 and acute myeloid leukemia.